Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. Kinarus’s unique and innovative combinatorial therapeutic candidate has broad potential to transform numerous therapeutic areas.

12 May 2023

First transaction on KIN001

Kinarus have announced the signing of an agreement with ChaoDain (Hangzhou) Investment Management (CDIM) for a CHF 1.5m convertible loan that will form the basis for the development of KIN001 in the treatment of idiopathic pulmonary fibrosis (IPF) in China. This is an important validation of the potential of KIN001 in IPF and could be the first of a sequence of transactions that result in development collaborations on KIN001, and not just in IPF.

We regard the investment by ChaoDain Investment Management, and the raising of the profile of KIN001 in IPF, as a significant positive step in validating KIN001 in its proposed inflammatory indications as well as providing a welcome cash inflow.

However we shall not be changing our valuation or forecasts until at least the release of Kinarus’ full-year 2022 results at the end of this month.

Download as a PDF file

Return to Kinarus AG

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Website design & development by Breckenridge